大剂量阿托伐他汀预防经皮冠状动脉介入治疗术患者心血管事件有效性的Meta分析
x
请在关注微信后,向客服人员索取文件
篇名: | 大剂量阿托伐他汀预防经皮冠状动脉介入治疗术患者心血管事件有效性的Meta分析 |
TITLE: | |
摘要: | 目的:系统评价大剂量阿托伐他汀预防经皮冠状动脉介入治疗(PCI)术患者心血管事件的有效性,以为临床提供循证参考。方法:计算机检索Medline、EMBase、Central、中国期刊全文数据库、万方数据库等,收集在常规治疗(对照组)的基础上加用大剂量阿托伐他汀(试验组)预防PCI术患者心血管事件的随机对照试验(RCT),对符合纳入标准的临床研究进行资料提取,并采用Cochrane 5.1.0系统评价员手册进行质量评价,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入12项RCT,合计2 081例患者。Meta分析结果显示,试验组患者PCI术心肌梗死发生率[OR=0.55,95%CI(0.43,0.71),P<0.001]、主要不良心血管事件发生率[OR=0.58,95%CI(0.44,0.78),P<0.001]均显著低于对照组,差异均有统计学意义。结论:大剂量阿托伐他汀可有效降低患者PCI术心肌梗死和主要不良心血管事件发生率。 |
ABSTRACT: | OBJECTIVE:To systematically review the effectiveness of high-dose atorvastatin in the prevention of cardiovascular events in patients with percutaneous coronary intervention(PCI), and provide evidence-based reference for clinical treatment. METHODS: Retrieved from Medline,EMBase, Central,CJFD and Wanfang database, randomized controlled trials(RCT)of high- dose atorvastatin (test group) based on conventional treatment (control group) in the prevention of cardiovascular events in patients with PCI were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with Cochrane 5.1.0 systematic reviewers manual. RESULTS:Totally 12 RCT were enrolled, involving 2 081 patients. Results of Meta-analysis showed, the incidence of myocardial infarction [OR=0.55,95%CI(0.43,0.71),P<0.001] and the main adverse cardiovascular events [OR=0.58,95%CI(0.44,0.78),P<0.001] in test group were significantly lower than control group, the differences were statistically significant. CONCLUSIONS: High-dose atorvastatin can effectively reduce the incidence of perioperative myocardial infarction and the main cardiovascular events in patients with PCI. |
期刊: | 2016年第27卷第9期 |
作者: | 付俊涛,娄小飞,孙志,杨翠,张丽霄,杜书章 |
AUTHORS: | FU Juntao,LOU Xiaofei,SUN Zhi,YANG Cui,ZHANG Lixiao,DU Shuzhang |
关键字: | 阿托伐他汀;经皮冠状动脉介入治疗术;Meta分析;有效性 |
KEYWORDS: | Atorvastatin; Percutaneous coronary intervention; Meta-analysis; Effectiveness |
阅读数: | 257 次 |
本月下载数: | 6 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!